Diabetic Foot Infections Clinical Presentation
- Author: Michael Stuart Bronze, MD; Chief Editor: Michael Stuart Bronze, MD more...
History
As previously mentioned, local trauma and/or pressure (often in association with lack of sensation because of neuropathy), in addition to microvascular disease, may lead to a diabetic foot infection. However, patients may not necessarily have a history of trauma or have suffered a previous infection.
Physical Examination
Cellulitis
Cellulitis may involve tender, erythematous, nonraised skin lesions on the lower extremity that may or may not be accompanied by lymphangitis. Lymphangitis suggests a group A streptococcal etiology. If bullae are present, S aureus is the most likely pathogen, but group A streptococci occasionally cause bullous lesions. No ulcer or wound exudate is present in patients with cellulitis.
Deep-skin and soft-tissue infections
Patients with deep-skin and soft-tissue infections may be acutely ill, with painful induration of the soft tissues in the extremity. These infections are particularly common in the thigh area, but they may be seen anywhere on the leg or foot. Wound discharge is usually not present.
In mixed infections that may involve anaerobes, crepitation may be noted over the afflicted area. Extreme pain and tenderness indicate the possibility of a compartment syndrome. Similarly, extreme pain may be an indication of infection with clostridial species (ie, gas gangrene). The tissues are not tense, and bullae may be present. If a discharge is present, it is often foul.
Acute osteomyelitis
Unless peripheral neuropathy is present, the patient has pain at the site of the involved bone. Usually, fever and regional adenopathy are absent.
Chronic osteomyelitis
In chronic osteomyelitis, the patient's temperature is usually less than 102°F. Discharge is commonly foul. No lymphangitis is observed, and pain may or may not be present, depending on the degree of peripheral neuropathy.
The deep, penetrating ulcers and deep sinus tracts (which are diagnostic of chronic osteomyelitis) are usually located between the toes or on the plantar surface of the foot. In patients with diabetes, chronic osteomyelitis usually does not occur on the medial malleoli, shins, or heels. (See the image below.)
Chronic diabetic ulceration with underlying osteomyelitis. Plain film radiograph exhibiting cortical disruption at the medial aspect of the first MTP joint. Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet. Nov 12 2005;366(9498):1695-703. [Medline].
Lipsky BA, Giordano P, Choudhri S, Song J. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate. J Antimicrob Chemother. Aug 2007;60(2):370-6. [Medline]. [Full Text].
Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother. Feb 2005;55(2):240-5. [Medline]. [Full Text].
Stein GE, Schooley S, Peloquin CA, Missavage A, Havlichek DH. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother. Oct 2007;60(4):819-23. [Medline]. [Full Text].
Wang S, Cunha BA, Hamid NS, Amato BM, Feuerman M, Malone B. Metronidazole single versus multiple daily dosing in serious intraabdominal/pelvic and diabetic foot infections. J Chemother. Aug 2007;19(4):410-6. [Medline].
Malabu UH, Al-Rubeaan KA, Al-Derewish M. Diabetic foot osteomyelitis: usefulness of erythrocyte sedimentation rate in its diagnosis. West Afr J Med. Apr-Jun 2007;26(2):113-6. [Medline].
Tan PL, Teh J. MRI of the diabetic foot: differentiation of infection from neuropathic change. Br J Radiol. Nov 2007;80(959):939-48. [Medline]. [Full Text].
US Food and Drug Administration. FDA Drug Safety Communication: Serious CNS reactions possible when linezolid (Zyvox®) is given to patients taking certain psychiatric medications. Available at http://www.fda.gov/Drugs/DrugSafety/ucm265305.htm. Accessed July 27, 2011.

